Free Daily Podcast Summary
The Readout Loud: Daily Summaries Delivered
by STAT
STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.
Latest Episodes
The most recent episodes — sign up to get AI-powered summaries of each one.
- 2 days ago36 min
411: Capricor's data clash and a fugitive in the C-suite
Is the Food and Drug Administration taking inconsistent approaches to Duchenne muscular dystrophy drugs? How will a new batch of drug executives shake up their companies? And why is Adam talking to a recruiter?We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast.It's a big week for FDA advisory committee meetings. Allison, Elaine, and Adam discuss Capricor Therapeutics' hearing in front of an FDA advisory committee. The company is asking the agency to approve its treatment for Duchenne, but advisers have questioned the data the company presented. They also discuss Replimmune's meeting with advisers to discuss its immunotherapy for melanoma.The hosts further discuss the latest news in the life sciences, including new details on how a fugitive worked as a biotech executive, cuts at GSK, and Sarepta Therapeutics' new CEO.
- 1 weeks ago1h 4m
410: A father’s mission to save his daughter, and allegations on telehealth GLP-1 prescribing
What does it take to develop a therapy for an ultra-rare disease? What are the allegations against a telehealth company that’s partnered with Novo Nordisk? And has a wanted fugitive been posing as a biotech executive? We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast. We speak with our colleagues Jason Mast and Matthew Herper about their impactful look at one father’s mission to develop a treatment for his daughter’s ultra-rare disease. The subject of that feature, Matt Wilsey, also joins us.
- 2 weeks ago35 min
409: Predicting biotech clinical trials & a new Alzheimer's drug controversy
On this week’s episode of "The Readout LOUD": The Kalshi prediction markets are coming for biotech, plus the controversy over an experimental Alzheimer’s disease treatment from Biogen. Kalshi, the maker of prediction markets, announced this week that it is expanding into biotech. Soon, you’ll be able to make bets on the outcomes of clinical trials and FDA drug reviews. Is that a good thing? We’ll discuss the issues with Jonathan Kimmelman, a bioethicist at McGill University who has researched prediction in clinical trials. We also chat about Biogen and its tau-lowering drug for Alzheimer’s. A mid-stage clinical trial presented this week showed the drug reduced levels of the tau protein and slowed the rate of cognitive decline in patients. But the data also raised a lot of questions that left experts and investors debating the drug’s future.
- 3 weeks ago43 min
408: Whistleblower takes on health insurance and FDA commissioner candidates
Why does getting family health insurance through a job cost as much as buying a new car? How did a whistleblower take on an insurance contractor? And who might be the new Food and Drug Administration commissioner? We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s weekly biotech podcast. STAT reporter Bob Herman joins us to discuss his new series, "Out of Pocket, Out of Reach," which dives into how soaring costs for health insurance are hurting Americans and small business owners. We also speak with Chris Deacon, who filed a whistleblower lawsuit after spotting how an insurer may have violated contracts to provide health benefits for New Jersey's state workers. We also discuss the latest news in life sciences, including Anthropic's push into drug development and Vertex's largest-ever acquisition.
- Jun 25, 202642 min
407: The mysterious case of Eli Lilly's obesity drug
Who got exclusive access to Eli Lilly's highly anticipated obesity candidate? Why are drugmakers spending so much money on acquisitions? And are hair loss drugs a good investment? We discuss all that and more on this week's episode of “The Readout LOUD,” STAT's biotech podcast. We bring on our colleague Lizzy Lawrence to discuss her scoop that Lilly and the Food and Drug Administration have allowed one person to receive the pharma company's obesity candidate, retatrutide, through the FDA’s “compassionate use” program. We also discuss the resurgence of M&A, Lilly's interest in a hair loss drug, and then the FDA's reversal on rare disease drugs.
- Jun 18, 202636 min
406: New hope in treating Huntington's disease and a report card on RFK Jr.'s promises
This week: New hope for people living with Huntington’s disease, and a report card on RFK Jr.’s effort to remake health in America. The Food and Drug Administration reversed its opposition to a closely watched gene therapy for Huntington’s disease, clearing a path for its maker, the biotech company UniQure, to file for U.S. approval. Joining us to discuss this new development and what it means for the Huntington’s community is Lauren Holder, a Huntington’s disease advocate who is living with the early stages of the disease. A pledge to “Make America Healthy Again” earned Robert F. Kennedy Jr. his job as the secretary of the Department of Health and Human Services. He entered the role with a long to-do list, and a goal of delivering measurable improvements within two years. How has he fared? Isabella Cueto, STAT’s chronic disease reporter, has been closely tracking Kennedy and the MAHA movement’s actions, and joins us to discuss.
- Jun 11, 202636 min
405: An obesity drug deep-dive, and peptides move mainstream
Can any of the new obesity medications in development stand out from the pack? Which company just broke records with its IPO? And will the Food and Drug Administration allow greater access to experimental peptides? We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast.[2:37 PM]Undark’s Sara Talpos joins the podcast to discuss her reporting on the peptide BPC-157, and how its jumped from a Croatian lab to bodybuilding forums on Reddit to the FDA. (STAT co-published Talpos articles; the second piece was was supported by the Pulitzer Center). We also discuss the latest news in the life sciences, including obesity data from the American Diabetes Association meeting and a record-breaking IPO.
- Jun 4, 202637 min
404: What RevMed's pancreatic cancer drug meant for one patient
Why did oncologists give a standing ovation to a data presentation on Revolution Medicines' pancreatic cancer drug, daraxonrasib? Why did biotech stocks perform so badly this week? And are concrete beaches better than normal beaches? We discuss all that and more on this week's episode of “The Readout LOUD,” STAT's biotech podcast. We bring on Leanna Stokes, who was diagnosed with metastatic pancreatic cancer in 2023. She discusses how participating in RevMed's trial for daraxonrasib has affected her disease and life, and what the drug means for patients and the field. We also chat about other data presented during last week's meeting of the American Society of Clinical Oncology, the market reaction to Abivax's ulcerative colitis data, and the upcoming meeting of the American Diabetes Association.
Get The Readout Loud summaries in your inbox
Free AI-powered daily recaps. Key takeaways, quotes, and mentions — in a 5-minute read.
Get Free Summaries →Free forever for up to 3 podcasts. No credit card required.
You Might Also Like
Listeners also like.
Plenary Session
Discusses medicine, oncology, and health policy with expert guests and critical analysis.
Stock Movers
Daily analysis of top-performing and struggling stocks across global markets, covering major sectors and breaking investment news.
Relentless Health Value
Healthcare professionals work to reduce waste and fix broken incentives in the U.S. medical system through transparency and practical solutions.
Unbiased Science
Two scientists analyze health topics using objective, evidence-based approaches to inform everyday decisions.
Drug Story
Each episode explores the unexpected stories behind prescription drugs and the business of treating illness.
The Pulse
Explores surprising stories in health and science, from operating rooms and labs to breakthrough innovations.
The Best One Yet
Daily business news explained through sharp analysis and witty commentary, delivered in concise 20-minute episodes.
Biostatistics Podcast
A podcast exploring various topics in biostatistics.
Pivot
Sharp, unfiltered analysis of tech, business, and politics with bold predictions and lively debate.
Science Magazine Podcast
Weekly episodes covering original scientific research, global science news, and expert commentary.
Solutions with Henry Blodget
Henry Blodget interviews experts in business, tech, and politics about practical solutions for building a better future.
CSPI Podcast
Conversations with CSPI scholars and experts on topics in science, technology, and politics.
About The Readout Loud
STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.
Customized Recaps
AI-powered recaps with compact key takeaways, quotes, and insights.
Straight to Your Inbox
Get key takeaways from The Readout Loud in a 5-minute read.
Save Hours Every Week
Stay current on your favorite podcasts without falling behind.
Frequently Asked Questions
What is Podzilla's The Readout Loud daily summary?
It's a free AI-powered email that summarizes new episodes of The Readout Loud as soon as they're published. You get the key takeaways, notable quotes, and links & mentions — all in a quick read.
How does the The Readout Loud podcast summary work?
When a new episode drops, our AI transcribes and analyzes it, then generates a personalized summary tailored to your interests and profession. It's delivered to your inbox every morning.
Is this an official The Readout Loud product?
No. Podzilla is an independent service that summarizes publicly available podcast content. We're not affiliated with or endorsed by STAT.
Can I get summaries of other podcasts too?
Absolutely! The free plan covers up to 3 podcasts. Upgrade to Pro for 15, or Premium for 50. Browse our full catalog at /podcasts.
How often does The Readout Loud release new episodes?
The Readout Loud publishes weekly. Our AI generates a summary within hours of each new episode.
What topics does The Readout Loud cover?
The Readout Loud covers topics including Business. Our AI identifies the specific themes in each episode and highlights what matters most to you.
Start getting The Readout Loud summaries tomorrow morning.
Free forever for up to 3 podcasts. No credit card required.
Free forever for up to 3 podcasts. No credit card required.